Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jan 7, 2021; 27(1): 69-79
Published online Jan 7, 2021. doi: 10.3748/wjg.v27.i1.69
Table 1 Baseline characteristics of patients who underwent endoscopic ultrasound-guided celiac plexus neurolysis [n (%), n = 58]
Independent variables
Total number
Age in yr, range (mean)54–73 (67)
Gender, female/male25/33
Symptom
Abdominal pain concomitant with jaundice Tumor largest dimension in mm, range (mean)6 (10.3)
Ascites, slight or mild24–100 (44.3)
Tumor location4 (6.9)
Pancreatic head/neck
Pancreatic body/tail18 (31.0)
Initial VAS score, range (mean)40 (69.0)
Tramadol use before EUS-CPN6-10 (8)
Dose in mg, range (mean)51 (87.9)
Ganglia visualized0-240 (40)
Invasion of celiac plexus42 (72.4)
Distant metastasis16 (27.6)
Injected alcohol dose in mL, range (mean)26 (44.8)
Procedure method5–20 (10)
Unilateral
Bilateral33 (56.9)
Intra-procedural decrease in heart rate25 (43.1)
decrease of ≥ 5 beats for ≥ 10 s
48 (82.8)
Table 2 Univariable analysis of variables associated with pain response after 1 wk in the enrolled cohort of 58 patients
Independent variables
OR
95%CI
P value
Age in yr 1.0840.60-3.880.212
Gender, female/male1.390.43-3.790.64
Symptom
Abdominal pain concomitant with jaundice1.290.53–3.260.581
Tumor largest dimension1.320.45-4.690.665
Ascites1.7720.59–6.840.437
Tumor location
Pancreatic head/neck2.0710.60-7.090.232
Pancreatic body/tail0.6170.65-10.400.094
Initial VAS score2.2310.76-5.410.132
Tramadol use before EUS-CPN1.3390.54-15.390.327
Invisible ganglia3.5741.80-14.240.003
Invasion of celiac plexus7.9222.24-25.930.001
Distant metastasis5.941.31–11.820.015
Injected alcohol dose3.8251.12–13.420.437
Procedure method
Unilateral1.6770.84–11.480.591
Bilateral0.4890.11–1.120.087
Intra-procedural decrease in heart rate 1.0110.91–2.080.933
Table 3 Multivariate analysis for predictors affecting pain response after 1 wk by endoscopic ultrasound-guided celiac plexus neurolysis
Independent variables
OR
95%CI
P value
Ganglia invisible4.92.25-17.910.011
Invasion of celiac plexus 13.23.02-46.270.003
Distant metastasis6.842.34–19.150.022
Table 4 Univariable analysis of variables associated with pain response after 4 wk in the enrolled cohort of 58 patients
Independent variables OR95%CIP value
Age in yr1.0910.63-3.940.209
Gender, female/male1.1240.47-3.990.532
Symptom
Abdominal pain concomitant with1.3840.43–4.820.618
jaundice1.4960.32-5.920.701
Tumor largest dimension1.9210.79–9.340.408
Ascites
Tumor location3.590.40-10.060.184
Pancreatic head/neck0.420.15-12.770.082
Pancreatic body/tail2.930.42-8.170.101
Initial VAS score2.910.24-19.400.149
Tramadol use before EUS-CPN4.021.62-13.270.003
Invisible ganglia8.842.11-23.320.001
Invasion of celiac plexus7.831.81–15.770.009
Distant metastasis4.901.32–17.910.394
Injected alcohol dose
Procedure method2.870.44–17.410.502
Unilateral0.540.16–1.990.093
Bilateral0.940.42–3.120.858
Intra-procedural decrease in heart rate
Table 5 Multivariate analysis for predictors affecting pain response after 4 wk by endoscopic ultrasound-guided celiac plexus neurolysis
Independent variables OR95%CIP value
Invisible ganglia5.852.66-22.730.037
Invasion of celiac plexus15.114.01-51.220.001
Distant metastasis8.592.16–27.020.019